Consultation on applications for authorisation of regulated products: Three CBD products as novel foods

Page 1 of 3

Closes 16 Jun 2026

Consultation Questions covering all four applications

Thank you for taking the time to read our consultation document. We would now be grateful if you could answer the following questions:

1. Please note that Food Standards Scotland may publish details that you supply in legitimate pursuit of the functions of the organisation. Do you agree to the publication of your personal details and response?
(Required)
2. What is your name?
3. What is your email address? If you enter your email address then you will automatically receive an acknowledgement email when you submit your response.
4. Are you responding as a private individual or on behalf of an organisation/company?
(Required)
5. Please provide the name, phone number and address of your organisation
6. Do you consider the labelling provisions with respect to the ADI to be sufficient to help consumers make safe choices when consuming multiple CBD products in a day?
(Required)
7. Do you consider the labelling proposals included in the draft risk management recommendations to be sufficient to mitigate against consumption by under 18s?
(Required)
8. Do you have any other comments about our approach to use labelling for the protection of vulnerable groups, or any of the specific labelling proposals for individual applications?
9. Do you have any concerns about the safety of the CBD products with respect to the intended consumers?
10. Do you have any comments on the impacts, if any, resulting from the legal status of CBD products authorised to contain trace amounts of THC and resulting complications, if any, relating to enforcement under drugs legislation or the Novel Food Regulations?
11. Are there any other impacts on enforcement you wish to make the FSS aware of?
12. Do you have any comments about how the data protection provisions in the draft risk management recommendations may impact CBD products, the CBD industry as a whole, or the enforcement of CBD products?
13. Should the CBD products be authorised, what impacts, if any, are there on consumers or businesses in relation to the marketing of CBD products?
14. Do you have any comments or concerns on the impacts of authorising or not authorising the CBD products? If in favour of authorisation, do you have any points about the terms on which the CBD products are authorised (outlined in the FSS risk management recommendations)?
15. Are there any other legitimate factors that should be considered by ministers that have not already been highlighted?
16. Do you have any other feedback on the information presented in the consultation, or on anything that has not been covered?